Clinically used drug arsenic trioxide targets XIAP and overcomes apoptosis resistance in an organoid-based preclinical cancer model

Shi L, Lu J, Xia X, Liu X, Li H, Li X, Zhu J, Li X, Sun H, Yang X. Clinically used drug arsenic trioxide targets XIAP and overcomes apoptosis resistance in an organoid-based preclinical cancer model. Chem Sci. 2024 May 3;15(22):8311-8322. doi: 10.1039/d4sc01294a. PMID: 38846391; PMCID: PMC11151819.
Like

Share this post

Choose a social network to share with, or copy the shortened URL to share elsewhere

This is a representation of how your post may appear on social media. The actual post will vary between social networks

Please sign in or register for FREE

If you are a registered user on WORC.Community, please sign in